Pressurized Intraperitoneal Aerosol Chemotherapy

Phase 2Small molecule

AAssistance Publique - Hôpitaux de Paris

Pressurized Intraperitoneal Aerosol Chemotherapy is one of 66 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaActive, not recruiting

Gastric CarcinomaActive, not recruiting

AdenocarcinomaPhase 1

Active, not recruiting

Gastric CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

337 competitors in Adenocarcinoma

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

47 2

Gemzar

Johnson & Johnson

Phase 3

16 3

Taxol

Teva

Phase 3

13 4

Cyramza

Eli Lilly

Phase 3

4 5

Ellence

Pfizer

Phase 3

3 6

Paraplatin

AAvyxa

Phase 3

7 7

Erbitux

IImclone

Phase 3

5 8

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

5 9

Camptosar

EEastern Cooperative Oncology Group

Phase 3

2 10

Conmana

BBetta Pharmaceuticals Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1Recruiting

Adenocarcinoma

NCT06743867

Clinical

Trials by Indication[1]

Adenocarcinoma1 trial

The Safety and Efficacy of Pressurized Intraperitoneal Aerosol Chemotherapy for Peritoneal Metastatic Adenocarcinoma

Recruiting·GGuangdong Provincial People's Hospital·Phase 1·NCT06743867·30 enrolled

Gastric Carcinoma1 trial

Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Gastric Carcinomatosis. Phase II Randomized Study

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04065139·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pressurized Intraperitoneal Aerosol Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pressurized Intraperitoneal Aerosol Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pressurized Intraperitoneal Aerosol Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAssistance Publique - Hôpitaux de Paris

Pressurized Intraperitoneal Aerosol Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Adenocarcinoma1 trial

Gastric Carcinoma1 trial

References

Drug Info

Quick Facts

Related News